Prognostic Effect of Isolated Nocturnal Hypertension in Chinese Patients With Nondialysis Chronic Kidney Disease

Cheng Wang, Yan Li, Jun Zhang, Zengchun Ye, Qunzi Zhang, Xinxin Ma, Hui Peng, Tanqi Lou, Cheng Wang, Yan Li, Jun Zhang, Zengchun Ye, Qunzi Zhang, Xinxin Ma, Hui Peng, Tanqi Lou

Abstract

Background: Isolated nocturnal hypertension (INH) has been studied among the general population and hypertensive patients. However, little insight is available on the prognostic effect of INH in patients with chronic kidney disease (CKD). This study investigated the prognostic effect of INH in a cohort of Chinese patients with nondialysis CKD.

Methods and results: A total of 588 Chinese CKD patients who were admitted to the Third Affiliated Hospital of Sun Yat-Sen University were enrolled in this study. We monitored blood pressure (BP) throughout the day and followed health outcomes in the 588 CKD patients admitted to our hospital division. We recorded time to total mortality, cardiovascular mortality, renal events, and cardiovascular events. A total of 370 (62.92%) individuals had nocturnal hypertension, which included 136 (23.13%) patients with INH. Multivariable Cox regression analyses showed that nocturnal BP was a significant risk factor for renal events and cardiovascular events in CKD patients, even when adjusted for clinic BP, 24-hour BP, or daytime BP. Patients with nocturnal hypertension showed a worse prognosis compared with patients with nocturnal normotension (P<0.05), and nocturnal hypertension (versus nocturnal normotension) was associated with an increased risk for renal events (hazard ratio [HR], 3.81; 95% CI, 1.74-8.36) and cardiovascular events (HR, 8.34; 95% CI, 1.98-35.07). In addition, patients with INH had a worse prognosis than patients with normotension (P<0.017), whereas INH (versus normotension) was associated with a higher risk of renal events (HR, 2.78; 95% CI, 1.16-6.65) and cardiovascular events (HR, 6.82; 95% CI, 1.52-30.63).

Conclusions: INH was associated with a poor prognosis in Chinese nondialysis CKD patients.

Keywords: ambulatory blood pressure monitoring; chronic kidney disease; hypertension; isolated nocturnal hypertension; kidney; kidney (diabetes); prognosis.

© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

Figures

Figure 1
Figure 1
Patient selection and assignment to different ambulatory blood pressure status. ABPM indicates ambulatory blood pressure monitoring; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
Figure 2
Figure 2
Kaplan–Meier survival curves as a function of patients with or without nocturnal hypertension. A, Cumulative survival curves for total mortality in patients with or without nocturnal hypertension. B, Cumulative survival curves for cardiovascular mortality in patients with or without nocturnal hypertension. C, Cumulative survival curves for renal events in patients with or without nocturnal hypertension. D, Cumulative survival curves for cardiovascular events in patients with or without nocturnal hypertension. P<0.001 indicated a comparison between the nocturnal normotension and nocturnal hypertension groups.
Figure 3
Figure 3
Kaplan–Meier survival curves as a function of patients with normotension (NT), isolated nocturnal hypertension (INH), or day‐night sustained hypertension (DNH). A, Cumulative survival curves for total mortality in patients with INH or NT or DNH. B, Cumulative survival curves for cardiovascular mortality in patients with INH or NT or DNH. C, Cumulative survival curves for renal events in patients with INH or NT or DNH. D, Cumulative survival curves for cardiovascular events in patients with INH or NT or DNH. P<0.001 indicated a comparison between these 3 groups.

References

    1. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010;268:456–467.
    1. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang JE, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H. Prevalence of chronic kidney disease in China: a cross‐sectional survey. Lancet. 2012;379:815–822.
    1. The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration Writing and global analysis group . Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014;2:634–647.
    1. Johnson ES, Thorp ML, Yang X, Charansonney OL, Smith DH. Predicting renal replacement therapy and mortality in CKD. Am J Kidney Dis. 2007;50:559–565.
    1. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17:2034–2047.
    1. Fan HQ, Li Y, Thijs L, Hansen TW, Boggia J, Kikuya M, Bjorklund‐Bodegard K, Richart T, Ohkubo T, Jeppesen J, Torp‐Pedersen C, Dolan E, Kuznetsova T, Stolarz‐Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka‐Jaszcz K, Imai Y, Ibsen H, O'Brien E, Wang J, Staessen JA. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens. 2010;28:2036–2045.
    1. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension. 2011;57:3–10.
    1. Yano Y, Kario K. Nocturnal blood pressure and cardiovascular disease: a review of recent advances. Hypertens Res. 2012;35:695–701.
    1. Li Y, Staessen JA, Lu L, Li LH, Wang GL, Wang JG. Is isolated nocturnal hypertension a novel clinical entity? Findings from a Chinese population study. Hypertension. 2007;50:333–339.
    1. Wang C, Deng WJ, Gong WY, Zhang J, Zhang QZ, Ye ZC, Lou T. Nocturnal hypertension correlates better with target organ damage in patients with chronic kidney disease than a nondipping pattern. J Clin Hypertens (Greenwich). 2015;17:792–801.
    1. Wang C, Zhang J, Liu X, Li C, Ye Z, Peng H, Chen Z, Lou T. Reversed dipper blood‐pressure pattern is closely related to severe renal and cardiovascular damage in patients with chronic kidney disease. PLoS One. 2013;8:e55419.
    1. Wang C, Deng WJ, Gong WY, Zhang J, Tang H, Peng H, Zhang QZ, Ye ZC, Lou T. High prevalence of isolated nocturnal hypertension in Chinese patients with chronic kidney disease. J Am Heart Assoc. 2015;4:e002025 doi: .
    1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23:3–16.
    1. Li Y, Wang JG. Isolated nocturnal hypertension: a disease masked in the dark. Hypertension. 2013;61:278–283.
    1. Andrassy KM. Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’. Kidney Int. 2013;84:622–623.
    1. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AR, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
    1. American Diabetes Association . Classification and diagnosis of diabetes. Diabetes Care. 2015;38(suppl):S8–S16.
    1. Gabbai FB, Rahman M, Hu B, Appel LJ, Charleston J, Contreras G, Faulkner ML, Hiremath L, Jamerson KA, Lea JP, Lipkowitz MS, Pogue VA, Rostand SG, Smogorzewski MJ, Wright JT, Greene T, Gassman J, Wang X, Phillips RA. Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKD. Clin J Am Soc Nephrol. 2012;7:1770–1776.
    1. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969.
    1. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D, Goldberg RJ, Hand MM, Jaffe AS, Julian DG, Levy D, Manolio T, Mendis S, Mensah G, Pajak A, Prineas RJ, Reddy KS, Roger VL, Rosamond WD, Shahar E, Sharrett AR, Sorlie P, Tunstall‐Pedoe H. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003;108:2543–2549.
    1. Pocock SJ, Clayton TC, Altman DG. Survival plots of time‐to‐event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359:1686–1689.
    1. Gonzalez RE, Hernandez A, Dibner C, Koehler BB, Pechere‐Bertschi A. Arterial blood pressure circadian rhythm: significance and clinical implications. Rev Med Suisse. 2012;8:1709–1712.
    1. Hermida RC, Smolensky MH, Ayala DE, Fernandez JR, Moya A, Crespo JJ, Mojon A, Rios MT, Fabbian F, Portaluppi F. Abnormalities in chronic kidney disease of ambulatory blood pressure 24 h patterning and normalization by bedtime hypertension chronotherapy. Nephrol Dial Transplant. 2014;29:1160–1167.
    1. Wang C, Zhang J, Liu X, Li CC, Ye ZC, Peng H, Chen Z, Lou T. Effect of valsartan with bedtime dosing on chronic kidney disease patients with nondipping blood pressure pattern. J Clin Hypertens (Greenwich). 2013;15:48–54.
    1. Rahman M, Greene T, Phillips RA, Agodoa LY, Bakris GL, Charleston J, Contreras G, Gabbai F, Hiremath L, Jamerson K, Kendrick C, Kusek JW, Lash JP, Lea J, Miller ER, Rostand S, Toto R, Wang X, Wright JJ, Appel LJ. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013;61:82–88.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi